BIGBEAR
PHARMACEUTICAL
Osimertinib is a third-generation targeted therapy for lung cancer, specifically designed to treat non-small cell lung cancer driven by specific genetic mutations.
AuthenticGuaranteeFast DeliveryPrivacy On November 16, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to an oral medication for the treatment of patients wit···【More】
Update: 08 May,2026Source: BigbearViews: 118
March 31, 2017 — AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Osimertinib (brand name: Tagrisso···【More】
Update: 08 May,2026Source: BigbearViews: 96
On April 18, 2018, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved the targeted therapy Osimertinib for the first-···【More】
Update: 07 May,2026Source: BigbearViews: 99
Osimertinib is a tyrosine kinase inhibitor used to treat patients with non-small cell lung cancer (NSCLC) whose tumors have been identified—via an FDA···【More】
Update: 07 May,2026Source: BigbearViews: 99
On December 21, 2020, AstraZeneca’s Osimertinib was approved in the United States for the adjuvant treatment of adult patients with early-stage epider···【More】
Update: 07 May,2026Source: BigbearViews: 91
On February 19, 2024, AstraZeneca announced that its drug, osimertinib, has received approval in the United States for use in combination with chemoth···【More】
Update: 07 May,2026Source: BigbearViews: 94
September 26, 2024, Cambridge, UK — AstraZeneca’s osimertinib has received approval in the United States for the treatment of adult patients with unre···【More】
Update: 07 May,2026Source: BigbearViews: 95
Osimertinib is indicated for the treatment of various types of non-small cell lung cancer (NSCLC). Before initiating treatment, an FDA-approved diagno···【More】
Update: 06 Mar,2026Source: BigbearViews: 112
Since its FDA approval in the United States in 2015, Osimertinib has been widely used and recognized globally. In China, Osimertinib is marketed and i···【More】
Update: 06 Mar,2026Source: BigbearViews: 121
Osimertinib is a targeted therapy, belonging to the third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors.Side effects r···【More】
Update: 06 Mar,2026Source: BigbearViews: 109
Osimertinib, as a third-generation EGFR-TKI, has become a breakthrough drug in the treatment of non-small cell lung cancer (NSCLC) due to its highly e···【More】
Update: 06 Mar,2026Source: BigbearViews: 112
On April 18, 2018, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) had approved osimertinib for first-line treatment of patient···【More】
Update: 06 Mar,2026Source: BigbearViews: 105
On November 16, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval to osimertinib for the treatment of patients with advan···【More】
Update: 06 Mar,2026Source: BigbearViews: 113
Osimertinib is a targeted therapy for non-small cell lung cancer. Common side effects include skin reactions (rash, dryness), gastrointestinal discomf···【More】
Update: 06 Mar,2026Source: BigbearViews: 113
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
